Physician profile
Amy E Backus
NPI 1851737787
$1,864.80
in general payments reported to CMS, 2019-2025
25 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.43 · 2023: $19.24 · 2024: $34.53 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $293.32 | 2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $273.95 | 2025 | |
| Pfizer INC. | $234.07 | 2025 | |
| Lilly USA, LLC | $170.14 | 2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $139.12 | 2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.09 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.58 | 2025 | Relistor, Trulance |
| Genentech USA, INC. | $71.43 | 2021 | |
| Axsome Therapeutics, INC. | $70.54 | 2025 | Auvelity |
| Exact Sciences Corporation | $44.09 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $43.94 | 2025 | |
| Janssen Pharmaceuticals, INC | $42.17 | 2025 | Spravato |
| Amgen INC. | $34.58 | 2025 | Repatha, Otezla |
| Lundbeck LLC | $28.61 | 2025 | Rexulti |
| Kyowa Kirin, INC. | $24.35 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $21.25 | 2025 | Skyclarys |
| Novartis Pharmaceuticals Corporation | $20.16 | 2025 | |
| Hologic Sales and Service, LLC | $19.49 | 2024 | Aptima |
| Neurocrine Biosciences, INC. | $19.24 | 2023 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $18.50 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.44 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $17.43 | 2025 | Arexvy, Shingrix |
| Dexcom, INC. | $16.71 | 2025 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $16.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Backus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.